Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Microbiol ; 5: 19, 2005 Apr 25.
Article in English | MEDLINE | ID: mdl-15850481

ABSTRACT

BACKGROUND: Thousands of different microorganisms affect the health, safety, and economic stability of populations. Many different medical and governmental organizations have created lists of the pathogenic microorganisms relevant to their missions; however, the nomenclature for biological agents on these lists and pathogens described in the literature is inexact. This ambiguity can be a significant block to effective communication among the diverse communities that must deal with epidemics or bioterrorist attacks. RESULTS: We have developed a database known as the Microbial Rosetta Stone. The database relates microorganism names, taxonomic classifications, diseases, specific detection and treatment protocols, and relevant literature. The database structure facilitates linkage to public genomic databases. This paper focuses on the information in the database for pathogens that impact global public health, emerging infectious organisms, and bioterrorist threat agents. CONCLUSION: The Microbial Rosetta Stone is available at http://www.microbialrosettastone.com/. The database provides public access to up-to-date taxonomic classifications of organisms that cause human diseases, improves the consistency of nomenclature in disease reporting, and provides useful links between different public genomic and public health databases.


Subject(s)
Bioterrorism , Communicable Diseases, Emerging/microbiology , Communicable Diseases, Emerging/parasitology , Databases, Factual , Animals , Bacteria/classification , Bacterial Infections/epidemiology , Bacterial Infections/microbiology , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/virology , Eukaryota/classification , Fungi/classification , Genetic Engineering , Humans , Mycoses/epidemiology , Mycoses/microbiology , Protozoan Infections/epidemiology , Protozoan Infections/parasitology , Virus Diseases/epidemiology , Virus Diseases/virology , Viruses/classification
2.
J Pharmacol Exp Ther ; 307(1): 24-33, 2003 Oct.
Article in English | MEDLINE | ID: mdl-12893848

ABSTRACT

Activation of the cell-surface receptor Fas can lead to apoptosis in parenchymal cells in the liver, and if severe enough, result in fulminant hepatic failure and animal death. In the present study, we have examined the roles played by the Bcl-2 family members Bcl-xL and Bid in regulating this response. To do this, we have developed chemically modified 2'-O-(2-methoxy) ethyl antisense inhibitors of both Bid and Bcl-xL expression. In Balb/c mice, dosing with these antisense oligonucleotides reduced expression of the targeted mRNA by greater than 80% in the liver. This reduction was highly dependent upon oligonucleotide sequence and oligonucleotide dose. Reduction of Bcl-xL expression resulted in a potentiation of Fas-mediated apoptosis in liver and significant increase of the lethality of Fas-mediated fulminant hepatitis (p < 0.0001). In contrast, reduction of Bid expression protected the animals against Fas-mediated fulminant hepatitis and death (p < 0.0001). Simultaneous dosing of mice with Bcl-xL and Bid-targeting antisense oligonucleotides resulted in an inhibition of expression of both targeted proteins and protection of the animals from Fas-mediated apoptosis. These results demonstrate, for the first time, the role of Bcl-xL in regulating responses to proapoptotic Fas signaling in mouse liver. In addition, this is the first reported example demonstrating the ability of antisense inhibitors to reduce expression of multiple proteins in animals by simultaneous dosing.


Subject(s)
Carrier Proteins/antagonists & inhibitors , Hepatitis, Animal/metabolism , Oligonucleotides, Antisense/pharmacology , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , fas Receptor/physiology , Animals , Apoptosis , BH3 Interacting Domain Death Agonist Protein , Carrier Proteins/biosynthesis , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Oxidation-Reduction , Proto-Oncogene Proteins c-bcl-2/biosynthesis , RNA, Messenger , Tumor Cells, Cultured , bcl-X Protein
3.
J Biol Chem ; 278(2): 1149-57, 2003 Jan 10.
Article in English | MEDLINE | ID: mdl-12407109

ABSTRACT

Previous studies showed that short term exposure of cells to high glucose destabilized protein kinase C (PKC) betaII mRNA, whereas PKCbetaI mRNA levels remained unaltered. Because PKCbeta mRNAs share common sequences other than the PKCbetaII exon encoding a different carboxyl terminus, we examined PKCbetaII mRNA for a cis-acting region that could confer glucose-induced destabilization. A beta-globin/growth hormone reporter con struct containing the PKCbetaII exon was transfected into human aorta and rat vascular smooth muscle cells (A10) to follow glucose-induced destabilization. Glucose (25 mm) exposure destabilized PKCbetaII chimeric mRNA but not control mRNA. Deletion analysis and electrophoretic mobility shift assays followed by UV cross-linking experiments demonstrated that a region introduced by inclusion of the betaII exon was required to confer destabilization. Although a cis-acting element mapped to 38 nucleotides within the betaII exon was necessary to bestow destabilization, it was not sufficient by itself to confer complete mRNA destabilization. Yet, in intact cells antisense oligonucleotides complementary to this region blocked glucose-induced destabilization. These results suggest that this region must function in context with other sequence elements created by exon inclusion involved in affecting mRNA stability. In summary, inclusion of an exon that encodes PKCbetaII mRNA introduces a cis-acting region that confers destabilization to the mRNA in response to glucose.


Subject(s)
Exons , Glucose/pharmacology , Isoenzymes/genetics , Protein Kinase C/genetics , RNA, Messenger/metabolism , Animals , Base Sequence , Cell Line , Globins/genetics , Half-Life , Molecular Sequence Data , Muscle, Smooth, Vascular/cytology , Oligonucleotides, Antisense/pharmacology , Protein Kinase C beta , RNA Splicing , Rats
4.
Pain ; 99(1-2): 11-9, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12237180

ABSTRACT

Extracellular adenosine triphosphate (ATP), acting at P2X ionotropic receptors, is implicated in numerous sensory processes. Exogenous ATP has been shown to be algogenic in both animals and humans. Research focus has been directed towards the P2X(3) receptor, as it is preferentially expressed on nociceptive C-fibers and its implication in pain processing is supported by an altered nociceptive phenotype in P2X(3) knock-out mice. In order to further characterize the role of P2X(3) receptor activation in nociception, we evaluated the effects of continuous intrathecal administration of P2X(3) antisense oligonucleotides for 7 days in the rat. P2X(3) receptor antisense oligonucleotide treatment significantly decreased nociceptive behaviors observed after injection of complete Freund's adjuvant (CFA), formalin or alphabeta-methylene ATP into the rat's hind paw. The anti-hyperalgesic effects of the antisense treatment in the CFA model of inflammatory pain were dose related. Similar effects were observed with two distinct P2X(3) antisense oligonucleotides. These behavioral effects were significantly correlated with a decrease in P2X(3) receptor protein expression in the dorsal root ganglia (DRG). In contrast, a decrease in P2X(3) receptor protein expression in the DRG did not affect nociceptive behavior in the carrageenan model of acute thermal hyperalgesia. P2X(3) receptor antisense oligonucleotide treatment also significantly reduced mechanical allodynia observed after spinal nerve ligation. Overall, the present data demonstrate that activation of P2X(3) receptors contribute to the expression of chronic inflammatory and neuropathic pain states and that relief form these forms of chronic pain might be achieved by selective blockade of P2X(3 )receptor expression or activation.


Subject(s)
Adenosine Triphosphate/analogs & derivatives , Neuralgia/therapy , Neurogenic Inflammation/therapy , Oligonucleotides, Antisense/pharmacology , Receptors, Purinergic P2/genetics , Acute Disease , Adenosine Triphosphate/pharmacology , Animals , Antineoplastic Agents/pharmacology , Chronic Disease , Hyperalgesia/therapy , Injections, Spinal , Ligation , Male , Nociceptors/drug effects , Pain Measurement , Rats , Rats, Sprague-Dawley , Receptors, Purinergic P2X3 , Spinal Nerves/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...